Real-world data used to compare MS treatments here's what they found
January 06, 2022
A news study comparing multiple sclerosis therapies, researchers report rituximab is more effective in reducing the rate of relapse than natalizumab; Dennis Bourdette, M.D., who was not involved in the study, says these particular findings might not affect how patients are treated, but the approach could prove valuable.